The demo obtained equally its Principal endpoints, with semaglutide 2.four mg demonstrating statistically important and exceptional improvements in liver fibrosis without worsening of steatohepatitis, in addition to resolution of steatohepatitis without worsening of liver fibrosis in those with MASH